Abstract
Cardiac amyloidosis must be suspected in all cases of hypertrophic cardiomyopathy with preserved left ventricular ejection fraction to allow specific management.
Final diagnosis needs pathological evidence, but bone scintigraphy may be an alternative for TTR amyloidosis.
Invasive samplings are limited by new tools.
Amyloidosis typing is required to start specific therapies if possible.
Main specific treatments that are available are chemotherapy for AL; transthyretin stabilizer or gene therapy, studied for TTR-related cardiac amyloidosis.